Javier F. Magrina

Laser therapy of vaginal intraepithelial neoplasia.

Abstract Laser therapy of gynecologic neoplasia is relatively new and there is minimal experience with vaginal intraepithelial neoplasia. Fifteen unselected patients with vaginal intraepithelial neoplasla were treated primarily with the carbon dioxide laser. The average follow-up is 15 months. At this time there have been two failures and two patients are currently being treated. Eleven patients treated with the laser have no evidence of disease. are discussed.

Intraperitoneal spillage of formalin after intravesical instillation

Abstract Intravesical instillation of formalin appears to be a method of choice in the control of massive hematuria following radiation cystitis. It is generally described as a safe, cheap, effective procedure. We report a case of intraperitoneal spillage of formalin and describe the metabolic and extensive medical problems encountered in the four-week period following the incident before the patients death.

Evaluation of groin and vulvar flap viability by the use of intravenous fluorescein

Abstract Postoperative necrosis or primary healing was predicted by the fluorescein test in most instances of groin and vulvar flaps. However, the extent of necrosis correlated poorly with the extent of areas of spotted fluorescence and nonfluorescence.

Malignant brenner tumor of the ovary. A case report: negative second look laparotomy following surgery, radiation and chemotheraphy

A patient with malignant ovarian Brenner tumor treated with surgery, radiation and chemotherapy is presented. She has remained free of disease fifteen months after negative second look laparotomy.

Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma

A review of 18 patients with Stage III epithelial ovarian carcinoma treated by surgery and followed by cyclophosphamide and cisplatinum combination chemotherapy is presented. At the end of 12 months from the initiation of chemotherapy, 88.9% of the patients were alive and 77.8% remained free of tumor progression. At the end of 2 years 77.8% of the patients were alive and 44.4% of the patients were free of tumor progression. The combination of cyclophosphamide and cisplatinum has low toxicity, a simple pattern of administration, and has provided satisfactory results.